PROTHENA CORP PUBLIC LTD CO

Prothena Corporation plc is a late-stage clinical biotechnology company specializing in protein dysregulation to address neurodegenerative and rare peripheral amyloid diseases. The company leverages its scientific expertise to develop a pipeline of therapeutic candidates for various indications and targets. Prothena's pipeline includes both wholly-owned and partnered programs aimed at treating diseases such as Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions. The company also utilizes its proprietary CYTOPE® technology to target intracellular disease pathways in the brain and periphery. Prothena was formed on September 26, 2012, in Ireland, and re-registered as an Irish public limited company on October 25, 2012. Its ordinary shares began trading on The Nasdaq Global Market under the symbol "PRTA" on December 21, 2012, and now trade on The Nasdaq Global Select Market. The company's strategy is to discover and develop novel therapies for diseases caused by protein dysregulation, where misfolded proteins aggregate to form amyloid, damaging vital organs. For example, Parkinson's disease involves neuronal dysfunction and loss due to the spread of toxic aggregated alpha-synuclein protein.